logo
Rare Earth Production Outside China 'Major Milestone'

Rare Earth Production Outside China 'Major Milestone'

An Australian firm's production of a heavy rare earth, a first outside of China, is a "major milestone" in diversifying a critical supply chain dominated by Beijing, experts say.
But the announcement by Lynas Rare Earths also illustrates how much more needs to be done to broaden the supply of elements critical for electric vehicles and renewable technology.
Rare earth elements (REE) are 17 metals that are used in a wide variety of everyday and high-tech products, from light bulbs to guided missiles.
Among the most sought-after are neodymium and dysprosium, used to make super-strong magnets that power electric car batteries and ocean wind turbines.
Despite their name, rare earths are relatively abundant in the Earth's crust. Their moniker is a nod to how unusual it is to find them in a pure form.
Heavy rare earths, a subset of overall REE, have higher atomic weights, are generally less abundant and often more valuable.
China dominates all elements of the rare earths supply chain, accounting for more than 60 percent of mining production and 92 percent of global refined output, according to the International Energy Agency.
Lynas said it produced dysprosium oxide at its Malaysia facility, making it the only commercial producer of separated heavy rare earths outside of China.
It hopes to refine a second heavy rare earth -- terbium -- at the same facility next month. It too can be used in permanent magnets, as well as some light bulbs.
It "is a major milestone," said Neha Mukherjee, senior analyst on raw materials at Benchmark Mineral Intelligence.
The announcement comes with China's REE supply caught up in its trade war with Washington.
It is unclear whether a 90-day truce means Chinese export controls on some rare earths will be lifted, and experts say a backlog in permit approvals will snarl trade regardless.
"Given this context, the Lynas development marks a real and timely shift, though it doesn't eliminate the need for broader, global diversification efforts," said Mukherjee.
Lynas did not say how much dysprosium it refined, and rare earths expert Jon Hykawy warned the firm faces constraints.
"The ore mined by Lynas contains relatively little of the heavy rare earths, so their produced tonnages can't be that large," said Hykawy, president of Stormcrow Capital.
"Lynas can make terbium and dysprosium, but not enough, and more is needed."
The mines most suited for extracting dysprosium are in south China, but deposits are known in Africa, South America and elsewhere.
"Even with Lynas' production, China will still be in a position of dominance," added Gavin Wendt, founding director and senior resource analyst at MineLife.
"However, it is a start, and it is crucial that other possible projects in the USA, Canada, Brazil, Europe and Asia, also prove technically viable and can be approved, so that the supply balance can really begin to shift."
China's domination of the sector is partly the result of long-standing industrial policy. Just a handful of facilities refining light rare earths operate elsewhere, including in Estonia.
It also reflects a tolerance for "in-situ mining", an extraction technique that is cheap but polluting, and difficult to replicate in countries with higher environmental standards.
For them, "production is more expensive, so they need prices to increase to make any seriously interesting profits," said Hykawy.
That is a major obstacle for now.
"Prices have not supported new project development for over a year," said Mukherjee.
"Most non-Chinese projects would struggle to break even at current price levels."
There are also technical challenges, as processing rare earths requires highly specialised and efficient techniques, and can produce difficult-to-manage waste.
Lynas has commissioned more processing capacity at its Malaysia plant, designed to produce up to 1,500 tonnes of heavy rare earths.
If that focused on dysprosium and terbium, it could capture a third of global production, said Mukherjee.
The firm is building a processing facility in Texas, though cost increases have cast doubt on the project, and Lynas wants the US government to pitch in more funds.
US firm MP Materials has also completed pilot testing for heavy rare earth separation and plans to boost production this year.
Canada's Aclara Resources is also developing a rare earths separation plant in the United States.
And Chinese export uncertainty could mean prices start to rise, boosting balance sheets and the capacity of small players to expand.
"The Lynas announcement shows progress is possible," said Mukherjee.
"It sends a strong signal that with the right mix of technical readiness, strategic demand, and geopolitical urgency, breakthroughs can happen."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The Risks of Foreign Investment in U.S. Life Sciences Companies — Why Founders Should Take Heed
The Risks of Foreign Investment in U.S. Life Sciences Companies — Why Founders Should Take Heed

Int'l Business Times

time2 days ago

  • Int'l Business Times

The Risks of Foreign Investment in U.S. Life Sciences Companies — Why Founders Should Take Heed

In recent years, Chinese investment in U.S. and global biotech and medtech has increased significantly. These partnerships can serve as strategic footholds, raising complex questions around security, sovereignty, and long-term strategy. Consider Grand Pharmaceutical Group, also known as Yuanda Pharmaceutical and Grand Pharma, which jointly acquired Australian firm Sirtex Medical, forged a nuclear medicine collaboration with Sirtex Medical U.S., and took an 87.5% stake in BlackSwan Vascular, a U.S.-based developer of vascular embolization technologies. On the surface, Grand Pharma looks like a modern success story. Hu Kaijun, a Chinese billionaire, holds a majority stake in Grand Pharma, positioning him as a key figure in the company's global expansion in the life sciences sector. Under his leadership, Grand Pharma has diversified its portfolio through strategic acquisitions and collaborations, enhancing its presence in the international market. But for U.S. life sciences stakeholders, don't be misled: Grand Pharma's rise isn't just a story of business savvy—it's a case study in how state-backed capital can reshape a company. And for founders, it's a reminder that funding sources can carry strategic baggage. Grand Pharma's aggressive expansion may reflect a broader trend of Chinese firms investing in advanced markets to access Western R&D and expand China's presence more deeply in the future of global biomedical innovation—a trend that raises serious concerns for U.S. interests. From State-Owned Roots to Global Reach Through strategic investments and collaborations, Kaijun and Grand Pharma continue to expand their footprint, resulting in the transfer of cutting-edge medical technologies from European and U.S. startups to China. Behind Grand Pharma's rapid rise lies a more complex history—one that raises questions about influence, oversight, and strategic intent. Before Grand Pharma was a global healthcare investor, it was a modest state-owned enterprise (SOE) in China under the purview of the Poverty Alleviation Office. Its mission: deliver pharmaceutical products as a public good, not a profit engine. But in the late 1990s and early 2000s, that began to change. A 2013 investigation by China Finance (CNFINA) suggested that Kaijun played a significant role in transforming the SOE into China Grand Enterprises through a series of complex transactions that have raised questions about corporate governance and asset valuation. One notable transaction highlighted in the CNFINA report involves Yanhuang Real Estate, a private firm not previously affiliated with the company. The firm purchased 50% of China Grand Enterprises from two state-owned shareholders for 50 million yuan. This transaction was justified using China Grand's initial registered capital of 100 million yuan. However, estimates based on the net assets held by China Grand at the time suggested that those shares were worth at least 145 million yuan, indicating a potential undervaluation of approximately 95 million yuan. The CNFINA report details that two additional state-owned entities transferred their 50% stake to four private investment firms, including Beijing Taihua Yongchang Investment and Beijing Dongfang Weichuang, for similarly underpriced amounts based on outdated registered capital. CNFINA's analysis estimated the value of these two transfers combined to have resulted in a total undervaluation of over 218 million yuan. This suspicious restructuring is significant because it offers a window into how power and capital were initially consolidated, and under what terms. Transactions that undervalue assets and move them out of public hands raise fundamental concerns about transparency, governance, and intent. When such origins lead to foreign acquisitions in sensitive sectors like biotechnology, it becomes even more important to scrutinize the business culture and strategic motivations behind the capital. In short, where the wealth comes from and how it was made offer important clues into how business leaders operate their companies. The Fine Print of Chinese Capital For U.S. life sciences startups, the lesson is clear: capital isn't neutral. The wrong investor can bring not just regulatory headaches but long-term strategic consequences. A growing list of cases tells a cautionary tale. Sirtex Medical When Grand Pharma and CDH Investments outbid Varian by a reported 20% to acquire Sirtex Medical, observers raised questions about the surprisingly high acquisition price. Through its subsidiary Chengdu Shetai, Grand Pharma has since leveraged Sirtex's platform to accelerate its development of nuclear medicine therapies. In cases of majority foreign ownership, especially by companies with potential state affiliations, it invites questions about data governance, manufacturing control, and regulatory visibility. More Lessons from BGI, WuXi, and Others Grand Pharma isn't the only example. Chinese biotech giants like BGI Group and WuXi AppTec have drawn attention in recent years over concerns related to data use, military ties, and participation in U.S. research networks. These cases underscore a growing sensitivity: capital flows from companies with strategic state interests may pose challenges in sensitive sectors like life sciences. A recent TechTimes article breaks down the core risks facing U.S. life sciences companies in the face of growing Chinese investment, from academic partnerships enabling access to sensitive research to financial ties that quietly shift control, and nefarious enterprises evading regulatory scrutiny. The piece argues that while the proposed BIOSECURE Act legislation is a step in the right direction, it lacks the enforcement teeth needed to truly safeguard American innovation in the life sciences sector. Ultimately, U.S. biotech and medtech startups must take proactive responsibility for who they partner with because policy alone won't protect what's not carefully guarded from the start. A Critical Reminder for Founders and CEOs: Capital Comes with Consequences U.S. life sciences startups face an increasingly complex landscape. Fast, global capital may seem like an obvious win, but it can introduce long-term complications. These include heightened regulatory oversight, potential deal restrictions, and reputational considerations. As geopolitical tensions evolve, particularly between the U.S. and China, biotech and medtech are emerging as points of scrutiny. In an interview on Chinese firms facing U.S. Commerce Department action related to AI, Gordon Chang, a senior fellow at the Gatestone Institute and a specialist on U.S.-China relations, stated, "all Chinese companies are a threat." While his comment was made in the context of national security and advanced technologies, it reflects a broader concern among some policymakers and analysts: that Chinese firms, regardless of sector, may operate with implicit state alignment, especially when national strategic interests are involved. For biotech and medtech companies, choosing the right partner now depends as much on who they are as what they offer. For the foreseeable future, U.S. startups should approach foreign investment, especially from state-influenced entities, with caution and care. This isn't just about one company or one country. It's about building resilient innovation ecosystems that can withstand geopolitical shifts while preserving trust, competitiveness, and scientific integrity.

US-China trade talks to move forward after Trump-Xi call – DW – 06/05/2025
US-China trade talks to move forward after Trump-Xi call – DW – 06/05/2025

DW

time3 days ago

  • DW

US-China trade talks to move forward after Trump-Xi call – DW – 06/05/2025

The US president said he spoke with Chinese leader Xi Jinping about trade issues and said US and Chinese negotiating teams will be meeting soon. US President Donald Trump said he had a "very good phone call" with China's President Xi Jinping on Thursday. In comments posted on his Truth Social platform, Trump said "some of the intricacies of our recently made, and agreed to, Trade Deal" had been discussed. The US president said the call lasted around one and a half hours and "resulted in a very positive conclusion for both Countries." Trump invited to China Trump said Xi "graciously invited" him and the first lady to visit China, to which he "reciprocated." "As Presidents of two Great Nations, this is something that we both look forward to doing," Trump said. US-China trade talks US and Chinese teams would be meeting "shortly" at a yet to be determined location the US leader said and would involve Secretary of the Treasury Scott Bessent, Secretary of Commerce Howard Lutnick, and US Trade Representative, ambassador Jamieson Greer. Trump emphasized that talks had focused almost entirely on trade with no discussions relating to Russia, Ukraine or Iran. The call comes amid a 90-day tariff truce that came into effect last month which paused a spiraling trade war between the world's two largest economies. Trump has lowered his 145% tariffs on Chinese goods to 30% for 90 days to allow for talks while China also reduced its taxes on US goods from 125% to 10%. Edited by: Wesley Rahn

How the fragile US-China trade truce is unraveling – DW – 06/05/2025
How the fragile US-China trade truce is unraveling – DW – 06/05/2025

DW

time3 days ago

  • DW

How the fragile US-China trade truce is unraveling – DW – 06/05/2025

Donald Trump has accused Beijing of breaching last month's deal to cut steep tit-for-tat tariffs. Could a much-awaited call between the US and Chinese presidents break the deadlock? The world exhaled when the United States and China unveiled a 90-day tariff truce last month, pausing the escalating trade war between the globe's largest and second-largest economies, which had rattled businesses and investors. The deal, after tense negotiations in Geneva, slashed US tariffs on Chinese imports from 145% to 30% and China's retaliatory levies on US goods from 125% to 10%. Just three weeks later, however, US President Donald Trump reignited tensions, saying that China had "totally violated" the truce deal, without providing further details. Trump later said his Chinese counterpart, Xi Jinping, was "extremely hard to make a deal with." China swiftly countered, asserting that Washington had imposed "discriminatory and restrictive measures" since the Geneva talks, pointing to US curbs on chip design software and warnings about artificial intelligence (AI) chips produced by Chinese tech giant Huawei. Deal stalled over US access to rare earths US policymakers have voiced frustration at China's stalling on export license approvals for rare earths and other elements needed in the high-tech, defense, and clean energy sectors. China, which dominates global rare-earth production with over two-thirds of supply and 90% of processing capacity, has imposed export restrictions on several key minerals. The US, lacking domestic rare-earth processing capacity, remains highly vulnerable to Beijing's restrictions. Confusion remains over what was agreed on rare earths in Geneva. In an interview with news agency Bloomberg on Wednesday, Cory Combs, head of critical-mineral supply chain research at Trivium China, said Washington believed that Beijing would "completely remove the requirement of an approval [for export licenses]," which Beijing said it did not agree to. Michael Hart, AmCham China president, told the Financial Times on Monday that China has now stepped up approvals to ship rare earths to several US carmakers, noting how "only a handful" of officials are handling thousands of applications. Trump's economic philosophy: A real plan or simply chaos? To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video Penny Naas, a distinguished fellow at the US-based German Marshal Fund think tank, thinks the rare earths are "China's biggest card," telling DW that "a key part of the negotiation will be when and how they liberalize the trade in those products." Naas expressed little surprise at the renewed war of words between Washington and Beijing, noting that, "You often see these highs and lows and even near-death experiences before deals are reached." But with the clock ticking until August 12 — when the 90-day pause expires — and both sides accusing the other of violations, the prospects for a lasting ceasefire and a long-term deal remain uncertain. Trump uses tariffs for maximum leverage Beyond securing access to China's rare minerals, the US seeks to cut its trade deficit with China, which was $295 billion (€259 billion) in 2024 — up nearly 6% on the previous year. The Trump administration has urged Beijing to boost purchases of American goods and eliminate non-tariff barriers, such as anti-monopoly probes targeting US companies and the designation of certain American firms as "unreliable entities." Washington has also demanded further economic reforms and an end to the manipulation of the Chinese yuan, which is kept artificially low to help boost exports. In April, when Trump announced his unprecedented tariffs, the yuan hit a 20-month low of 7.2038 against the dollar and is expected to weaken further if the higher US levies are reinstated. Trump has also pressed China to strengthen efforts to curb illegal immigration and halt exports of precursor chemicals used to produce fentanyl, an opioid fueling a public health crisis in the US. Will Trump-Xi call break the impasse? With US Treasury Secretary Scott Bessent acknowledging last week that negotiations have "stalled," all eyes are on whether a call between Trump and Xi will break the tariff deadlock. The US president has said for months that the two leaders were due to speak and even spoke of traveling to China for talks, without a public response from Beijing. US President Donald Trump said his Chinese counterpart is 'extremely hard' to make a deal with Image: Francis Chung/Imago The White House said Monday that a Trump-Xi call was "likely" to take place this week, a development that Antonio Fatas, an economics professor at INSEAD business school, said the US president would see as "his victory." "Trump's typically the one who calls people and tells them what to do," Fatas told DW. "But with a powerful player like China, that's not going to work. I wouldn't be surprised if China postpones the call." Although Trump will get the chance to talk to other world leaders on the sidelines of the upcoming G7 and NATO summits, the US and Chinese presidents aren't likely to meet in person until later in the year, signaling a protracted tussle that could last several more months. Tariff court battle plays into China's hands Another boon to China could be the lack of clarity over Trump's unprecedented tariffs after a US trade court last week ruled they were illegal. Although a higher court temporarily reinstated the levies, the White House has threatened to go to the Supreme Court for the ultimate ruling. "There may be a hesitancy to go all in on an offer at this moment when there's a large lack of clarity about the US position," the German Marshall Fund's Naas told DW. INSEAD's Fatas, meanwhile, predicted that the truce would be extended beyond the 90 days, adding: "Until I see the possibility of a real compromise on both sides, I'll remain very cautious and uncertainty remains incredibly high." Tariffs distract from US-China tech battle Both the Trump and Biden administrations have prioritized maintaining the US's technological edge over China, but there are growing concerns that the tariff policies are diverting resources and focus from US firms' ability to achieve this goal. Investor nervousness that the tariffs could cause a US recession has intensified. The tariffs have already increased costs and strained budgets for American tech firms, limiting their capacity to invest in research and development (R&D) at a critical time. With tariffs consuming significant attention among US policymakers, initiatives to bolster domestic innovation risk being sidelined. NVIDIA profits up, despite trade war challenges To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video Beijing, meanwhile, has doubled down on the need to reduce its dependence on US technology. Through substantial state subsidies, China has advanced its capabilities in AI, quantum computing, advanced chip production, and 6G telecommunications, narrowing the technological gap with the US. Naas thinks that China has now caught up on "most of the technological advantage the US thought it had" and that US companies say they're "falling behind while spending all their time on reorienting their supply chains." "Is that the best use of their time when we're in hand-to-hand combat on the future of technology?" she asks. Edited by: Uwe Hessler

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store